HCPLive Five - Pulmonology Updates at ATS International Conference 2025

With many different clinicians, researchers, and industry leaders convening in San Francisco, the American Thoracic Society (ATS) 2025 International Conference once again solidified its status as a cornerstone event in the field of pulmonology. The annual conference included groundbreaking data that spanned across a wide range of respiratory conditions, from chronic obstructive pulmonary disease (COPD) and asthma to interstitial lung diseases and pulmonary infections—fresh insights were offered into disease management, pathophysiology, and therapeutic innovations.

As part of our on-site coverage, the HCPLive editorial team reported directly from the conference floor, capturing late-breaking data, conducting exclusive interviews with pulmonology experts, and spotlighting pivotal sessions. In this edition of the 'HCPLive Five,' the team presents 5 standout video interviews, including conversations regarding novel findings from high-impact clinical trials shaping the future of pulmonary medicine as well as coverage of topics highlighted in sessions.

Vaccine Policies and Public Health Concerns in Immunization Science, with Grace Lee, MD, MPH

Following her presentation titled ‘Vaccines in the Crosshairs: Facing Contemporary Challenges in Immunization Science,’ Grace Lee, MD, MPH—known for her work as a professor of pediatrics at Stanford University School of Medicine—spoke about contemporary challenges in immunization science on the policy side.

Significance of New Nerandomilast Findings for Pulmonary Fibrosis, with Toby Maher, MD, PhD

Another interview at ATS 2025 highlighted new phase 3 findings from the FIBRONEER-IPF and FIBRONEER-ILD studies. These data suggested that nerandomilast met its primary endpoint in both studies assessing patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF), and the data were highlighted by trial investigator and professor of Clinical Medicine at USC’s Keck School of Medicine, Toby Maher, MD, PhD.

Subgroup Findings on Brensocatib for Non-Cystic Fibrosis Bronchiectasis, with James D. Chalmers, MBChB, PhD

Brensocatib, a drug currently under Priority Review with the US Food and Drug Administration (FDA), was discussed in another interview regarding its impacts on non-cystic fibrosis bronchiectasis in the ASPEN study. The findings were discussed at ATS by James D. Chalmers, MBChB, PhD, professor of respiratory research at the University of Dundee.

24-Month Findings on Macitentan, Tadalafil for Pulmonary Arterial Hypertension, with Kelly Chin, MD

Another interview featured at ATS regarded positive data released from the 24-month open-label extension of the A DUE trial, assessing a macitentan and tadalafil fixed-dose combination treatment (OPSYNVI) in a single tablet form for pulmonary arterial hypertension (PAH). The late-breaking data were highlighted by Kelly Chin, MD, lead investigator and professor of Internal Medicine and Director of Pulmonary Hypertension Clinical Research at UT Southwestern Medical Center.

Barriers to Immunizations Among Children in the US and Worldwide, with Arthur Reingold, MD

Arthur L. Reingold, MD, professor of epidemiology at UC Berkeley Public Health, interviewed with HCPLive regarding the biggest takeaways from his talk titled ‘The Global Immunization Divide: Overcoming Barriers to Universal Vaccine Coverage.’